Key Information for Pet Owners on TANOVEA-CA1

TANOVEA®-CA1 is designed to target lymphoma cells and attack them

  • Accumulates in rapidly dividing lymphoma cells and causes those cells to die

TANOVEA-CA1 demonstrated a reasonable expectation of effectiveness in clinical studies

  • Studied in clinical trials in 22 dogs receiving TANOVEA-CA1 once every three weeks
  • 77% of dogs with lymphoma responded to treatment
  • Responses seen in dogs new to treatment and in dogs who stopped responding to conventional chemotherapy

TANOVEA-CA1 is generally well tolerated

  • Common side effects include decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems
  • Other more serious side effects may occur – consult your veterinarian for additional information

TANOVEA-CA1 is convenient for you and your dog

  • One dose every three weeks
  • Only five visits for a full treatment

How much does TANOVEA-CA1 cost?

TANOVEA-CA1 requires a prescription from a licensed veterinarian. Pet owners should consult their veterinarian for information about TANOVEA-CA1 pricing.

How does TANOVEA-CA1 work?

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.


CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.


Important Safety Information: TANOVEA®-CA1 (rabacfosadine for injection) is not for use in humans and should be kept out of the reach of children. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and can cause birth defects and affect female and male fertility. Pregnant and breast-feeding women should not prepare or administer the product. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA®-CA1. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Most common adverse reactions included diarrhea, neutropenia, hyporexia, weight loss, and lethargy.  Please see the package insert for full prescribing information.